These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38055240)

  • 1. Psilocybin in Bipolar II Study Provides Preliminary Data on Safety.
    Yaden DB; Gukasyan N; Nayak SM
    JAMA Psychiatry; 2024 Jun; 81(6):541-542. PubMed ID: 38055240
    [No Abstract]   [Full Text] [Related]  

  • 2. Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety.
    Fried EI; Cristea IA; Naudet F
    JAMA Psychiatry; 2024 Jun; 81(6):633-634. PubMed ID: 38598200
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety-Reply.
    Aaronson ST; van der Vaart A; Sackeim HA
    JAMA Psychiatry; 2024 Jun; 81(6):634. PubMed ID: 38598225
    [No Abstract]   [Full Text] [Related]  

  • 4. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.
    Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T
    JAMA Psychiatry; 2024 Jun; 81(6):555-562. PubMed ID: 38055270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of psilocybin on treatment-resistant depression: A systematic review and meta-analysis.
    Fang Q; Chan VKY; Chan SSM; Jiao Y; Wang J; Li X
    Psychiatry Res; 2024 Jul; 337():115960. PubMed ID: 38781672
    [No Abstract]   [Full Text] [Related]  

  • 6. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption.
    Morton E; Sakai K; Ashtari A; Pleet M; Michalak EE; Woolley J
    J Psychopharmacol; 2023 Jan; 37(1):49-60. PubMed ID: 36515370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
    Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
    J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psilocybin: Good Trip or Bad Trip.
    Sellers EM
    Clin Pharmacol Ther; 2017 Oct; 102(4):580-584. PubMed ID: 28548221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
    Bogenschutz MP; Forcehimes AA; Pommy JA; Wilcox CE; Barbosa PC; Strassman RJ
    J Psychopharmacol; 2015 Mar; 29(3):289-99. PubMed ID: 25586396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
    Studerus E; Kometer M; Hasler F; Vollenweider FX
    J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Not imagining it. Research into hallucinogens cautiously resumes.
    Biello D
    Sci Am; 2006 Nov; 295(5):33-5. PubMed ID: 17076078
    [No Abstract]   [Full Text] [Related]  

  • 13. Ethnobotany of psilocybin mushrooms, especially Psilocybe cubensis.
    Badham ER
    J Ethnopharmacol; 1984 Apr; 10(2):249-54. PubMed ID: 6539409
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacology of psilocybin.
    Passie T; Seifert J; Schneider U; Emrich HM
    Addict Biol; 2002 Oct; 7(4):357-64. PubMed ID: 14578010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hallucinogenic mushrooms in Denmark].
    Holm JW; Ebbehøj NE; Fjeldberg IA
    Ugeskr Laeger; 1997 Aug; 159(34):5116-8. PubMed ID: 9297322
    [No Abstract]   [Full Text] [Related]  

  • 17. Psilocybin: a pharmacological profile.
    Aboul-Enein HY
    Am J Pharm Sci Support Public Health; 1974; 146(3):91-5. PubMed ID: 4853936
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans.
    Gouzoulis-Mayfrank E; Thelen B; Maier S; Heekeren K; Kovar KA; Sass H; Spitzer M
    Neuropsychobiology; 2002; 45(4):205-12. PubMed ID: 12097810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
    Carbonaro TM; Bradstreet MP; Barrett FS; MacLean KA; Jesse R; Johnson MW; Griffiths RR
    J Psychopharmacol; 2016 Dec; 30(12):1268-1278. PubMed ID: 27578767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.
    Erritzoe D; Barba T; Spriggs MJ; Rosas FE; Nutt DJ; Carhart-Harris R
    J Psychopharmacol; 2024 May; 38(5):458-470. PubMed ID: 38520045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.